Mayo Clinic: Cholangiocarcinoma trials

The registry lists 18 Cholangiocarcinoma studies with Mayo Clinic as lead sponsor. 6 are open to participants now and 3 have results posted.

Phase 1 8Phase 2 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)Enrolling by invitationNCT06474091
• Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT06058663Phase 1
• Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC PatientsRecruitingNCT04753996
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2
• Intravital Microscopy in Human Solid TumorsRecruitingNCT03823144Not applicable
• Biobank for Cholestatic Liver Diseases.RecruitingNCT03445585
• Prospective Evaluation of Biliary Tissue Sampling With ERCPCompletedNCT04572711Results posted
• Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract CancerCompletedNCT04072445Phase 2Results posted
• TAS-102 in Treating Advanced Biliary Tract CancersCompletedNCT03278106Phase 2Results posted
• NXP800 for the Treatment of Patients With Advanced or Metastatic CholangiocarcinomaTerminatedNCT06420349Phase 1
• Liver and Biliary Tumor Tissue RegistryTerminatedNCT02917759
• Extracellular RNA Markers of Liver Disease and CancerTerminatedNCT02908048
• Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic CholangiocarcinomaWithdrawnNCT02856568Phase 1
• Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or SurgeryCompletedNCT01888302Phase 1
• Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)CompletedNCT00955149Phase 1
• Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard TherapyCompletedNCT00949949Phase 1
• Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal CancerCompletedNCT00836992
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal CancerCompletedNCT00654160Phase 1